TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03110523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X0002
Description: All subjects who provide informed consent will initiate the Screening Period of at least 14 (±3) days for the assessment of eligibility including radiographic evaluation of the lumbar spine. X-ray images must be collected within 4-11 hours after the subject wakes up. Those subjects who meet preliminary eligibility criteria will be treated with placebo in a subject-blind manner for 14(±3) days from Screening Visit to Day 1. Subjects with a placebo response exceeding 25% improvement in the average NPRS score over the previous 7 days will be excluded. Subjects with a Lane grading of 1 or 2 on their neutral lateral lumbar spine film per the central radiologist are eligible to be enrolled. At Day 1, eligible subjects will be randomly assigned to 1 of 2 treatment groups in a 1:1 ratio with a 1:1 ratio of active:placebo within each treatment group, and stratified evenly according to Lane Radiographic Grading Scale summary score (1 or 2) and gender.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X0002
Description: All subjects who provide informed consent will initiate the Screening Period of at least 14 (±3) days for the assessment of eligibility including radiographic evaluation of the lumbar spine. X-ray images must be collected within 4-11 hours after the subject wakes up. Those subjects who meet preliminary eligibility criteria will be treated with placebo in a subject-blind manner for 14(±3) days from Screening Visit to Day 1. Subjects with a placebo response exceeding 25% improvement in the average NPRS score over the previous 7 days will be excluded. Subjects with a Lane grading of 1 or 2 on their neutral lateral lumbar spine film per the central radiologist are eligible to be enrolled. At Day 1, eligible subjects will be randomly assigned to 1 of 2 treatment groups in a 1:1 ratio with a 1:1 ratio of active:placebo within each treatment group, and stratified evenly according to Lane Radiographic Grading Scale summary score (1 or 2) and gender.
Study: NCT04041674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IHV01 Protein
Description: Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IHV01 Protein
Description: Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Protein Placebo
Description: Sodium Chloride for Injection, 0.9% USP~Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Protein Placebo
Description: Sodium Chloride for Injection, 0.9% USP~Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Protein Placebo
Description: Sodium Chloride for Injection, 0.9% USP~Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose
Study: NCT05490719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: QL1706 is a humanized anti-PD1 IgG4 and anti-CTLA-4 IgG4 antibody.
Study: NCT06175806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Oral Film
Description: 5-hydroxytryptamine (5-HT) receptor antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron Oral Liquid Product
Description: 5-hydroxytryptamine (5-HT) receptor antagonist
Study: NCT05101122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dosing 1: Atomoxetine
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD313
Description: Escalating dose of AD313; Oral administration at bedtime
Study: NCT05836506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903 Tablet Form 1
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903 Tablet Form 1
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903 Tablet Form 1
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903 Tablet Form 1
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903 Tablet Form 2
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903 Tablet Form 2
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903 Tablet Form 2
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903 Tablet Form 2
Description: Oral Tablets
Study: NCT05726305

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Live donor uterus transplantation
Description: Transplantation of uterus from a living donor.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deceased donor uterus transplantation
Description: Transplantation of uterus from a deceased brain-dead donor.
Study: NCT06332599

Intervention type: DRUG
Intervention: BQT
Description: PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, tetracycline 500 mg four times a day, and metronidazole 400 mg four times a day

Intervention type: DRUG
Intervention: PBM4M4
Description: PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg four times a day, and metronidazole 400 mg four times a day

Intervention type: DRUG
Intervention: PBM3M3
Description: PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg three times a day, and metronidazole 400 mg three times a day

Intervention type: DRUG
Intervention: PBM2M4
Description: PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg twice daily, and metronidazole 400 mg four times a day

Intervention type: DRUG
Intervention: PBM2M3
Description: PPI（esomeprazole or vonoprazan), bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg twice daily, and metronidazole 400 mg three times a day
Study: NCT06163443

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B
Description: MTHFR, MTR, and MTRR polymorphysm based L-methylfolate (1 mg), P5P (pyridoxal-5-phosphate, 50 mg), and Methylcobalamin (500 mcg) prescription

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MTHFR, MTR, and MTRR polymorphysm based placebo prescription
Study: NCT05274815

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab subcutaneous injection
Study: NCT05371717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Domiciliary use of Biorepair Total Protection + Biorepair Shock Treatment
Description: Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biorepair Total Protection
Description: Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.
Study: NCT05265429

Intervention type: GENETIC
Intervention: Data and Specimen Collection
Description: * Provide research team access to relevant medical records~* Answer two (2) short questionnaires at time of consent~* Provide up to 5 tubes (37 ml) of blood at or near the time of consent, and/or saliva sample~* Consider consenting to other optional parts of the research such as:~  * Providing additional blood or tissue samples in the future (optional)~ * Providing permission for obtainment of stored tissue specimens from lung cancer surgeries or biopsies from the pathology departments where they have been stored (optional)
Study: NCT06533787

Intervention type: DEVICE
Intervention: Echocardiography
Description: Functional echocardiography assessment

Intervention type: DEVICE
Intervention: Echocardiography
Description: Functional echocardiography assessment
Study: NCT06030648

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (IV-MSC)
Description: Patients will receive 1 infusion (1 x 106 cells/kg on day 0) then be followed for 8 weeks from the infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (IV-MSC)
Description: Patients will receive 1 infusion (1 x 106 cells/kg on day 0) then be followed for 8 weeks from the infusion.
Study: NCT06445530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MFeast ENHANCED
Description: Intervention group will initially receive prepared MTF (low carbohydrate, low-fat meals, which have been shown to improve glycemia in people with prediabetes) delivered by MFeast (10 meals weekly); Tailored Medical Nutrition Therapy (MNT) delivered by dieticians from MFeast via monthly phone calls and focused on only: ↓sugar-sweetened beverages and ↑fruit and vegetable consumption; Lactation snack bundles to boost milk supply + structural support for breastfeeding/pumping via lactation consultants and pumping supply subsidization; culturally-adapted seasoning bundles; and dependent meal boxes for children in the household (i.e., will include 10 developmentally appropriate snack and small meal bundles, for up to 24 weeks. At postpartum week 8 participants will be offered a transition from prepared medically tailored meals to Instacart fresh food delivery (via study team-crafted virtual grocery store) for 16 more weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MFeast Usual Care
Description: Those assigned to the MFeast Usual Care group will receive prepared MTF delivered by MFeast and as needed MNT from 1 to 24 weeks postpartum.
Study: NCT05222334

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrafascial interscalene brachial plexus block
Description: After sterilization of skin with povidone-iodine (betadine) and skin infiltration with 1-3ml lidocaine 1%, interscalene brachial plexus block will be performed using an ultrasound machine (Phillips Cx-50,Amsterdam, Netherlands) with a linear probe (L12-3 MHz) will be used in both groups. The US transducer will be placed under aseptic fashion on the lateral side of the neck at the cricoid cartilage level to view three hypoechoic structures, that represent the roots of the brachial plexus.~The two outermost nerve roots (C5 and C6) between the anterior and the middle scalene muscles will be identified and the local anesthetic (10 ml 0.5% bupivacaine) is then injected, so that spread will be seen immediately between the C5 and the C6 nerve roots.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extrafascial interscalene brachial plexus block group
Description: Final needle tip position will be 4 mm lateral to the brachial plexus sheath, at a level equidistant between C5 and C6 roots. The distance of 4 mm is chosen according to the calculated success rate over 90% reported. the local anesthetic (10 ml 0.5% bupivacaine) is then injected

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: bupivacaine
Study: NCT05015933

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pump refill procedure at home
Description: Implantable pump refill is performed at home
Study: NCT05358106

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AntiBKV
Description: AntiBKV neutralising antibody

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution with no active ingredients
Study: NCT05279001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablet
Description: Orally administered, twice a day
Study: NCT06265064

Intervention type: DIAGNOSTIC_TEST
Intervention: STOP-Bang score >= 3 with factors predicting difficult intubation
Description: patients with STOP-Bang score \>= 3 with Mallampati score ≥ 3 or neck circumference \>42 cm or mentothyroid distance \<6 cm

Intervention type: DIAGNOSTIC_TEST
Intervention: STOP-Bang score >= 3 with factors predicting difficult intubation
Description: patients with STOP-Bang score \>= 3 with Mallampati score ≥ 3 or neck circumference \>42 cm or mentothyroid distance \<6 cm
Study: NCT05493215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Therapeutic drug level monitoring with plans to increase to adjust drug dosage based on levels and patient symptoms.
Study: NCT04985968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobitolimod 250 mg
Description: Rectal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobitolimod 500 mg
Description: Rectal administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rectal administration
Study: NCT06294054

Intervention type: COMBINATION_PRODUCT
Intervention: neoadjuvant chemotherapy with cisplatine
Description: Blood from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine

Intervention type: COMBINATION_PRODUCT
Intervention: neoadjuvant chemotherapy with cisplatine
Description: Blood from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine

Intervention type: COMBINATION_PRODUCT
Intervention: neoadjuvant chemotherapy with cisplatine
Description: Blood from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine
Study: NCT05253820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: distal radial approach
Description: coronary diagnosis and intervention via distal vs conventional radial approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional radial access
Description: conventional radial access
Study: NCT05625308

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate, Folic acid, Vitamin B12, and Hyaluronic Acid
Description: One tablet per day containing 200 mg of EGCG, 400 mcg of Folic Acid, 1 mg of Vitamin B12 and 50 mg of Hyaluronic Acid.
Study: NCT03990493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue Virus-1 #45AZ5 (PV-001-DV)
Description: Intratumoral injection of PV-001-DV (1 injection)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Monocyte-derived Lysate Pulsed Dendritic Cells (PV-001-DC)
Description: IV Infusion of PV-001-DC (every 3 weeks for total of 4 infusions)
Study: NCT04979650

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone succinate
Description: 1 gram of methylprednisolone succinate within 500 ccs of normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone succinate
Description: 1 gram of methylprednisolone succinate within 500 ccs of normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 500 g of normal saline without methylprednisolone succinate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 500 g of normal saline without methylprednisolone succinate
Study: NCT05463692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Camelia Cohort
Description: Through the HealthMpowerment (HMP) app tailored for women, we will be able to provide informational content, access to resources, PrEP locators and additional gamification features to optimally engage and retain our cohort, which may support linkage to PrEP care.
Study: NCT05994196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimum, a secondary prioritization software of patients in the pediatric emergency department (ED)
Description: Optimum®'s purpose is to remove the mental load of prioritization from the Pediatric ED staff. The software first prioritizes the triage of new patients by the ED staff and the first evaluation of a new patient by the medical team. Optimum® then prioritizes blood sample collections and care (for nurses) and checks on imaging results, blood test results or an evaluation by a specialist (for physicians). Lastly, Optimum® prioritizes the final step in patient management by a senior physician, when appropriate.
Study: NCT05663879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID120040002
Description: Drug: ID120040002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID120040002
Description: Drug: ID120040002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID120040002
Description: Drug: ID120040002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID120040002
Description: Drug: ID120040002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID120040002
Description: Drug: ID120040002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID120040002
Description: Drug: ID120040002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID120040002
Description: Drug: ID120040002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID120040002
Description: Drug: ID120040002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID120040002
Description: Drug: ID120040002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound-X
Description: Drug: Compound-X

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: Placebo comparator
Study: NCT05114239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol 0.25% Ophthalmic Solution
Description: Applied to treatment side prior to standard wound care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Wound Care
Description: Wound is washed twice a day with soap and then petrolatum and a bandage is applied.
Study: NCT06109025

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FESIA GRASP
Description: The Fesia Grasp device is based on the superficial electrical stimulation of the forearm musculature to provoke flexion and extension movements of the wrist, thumb, index finger and fingers 3, 4 and 5.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VIRTUAL REHAB
Description: VirtualRehab is a therapeutic physical rehabilitation tool that uses virtual reality to provide therapy for patients with neurological or musculoskeletal disorders; providing a wide range of activities designed to improve mobility, coordination and strength.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: GLOBUS ELITE
Description: is an electro-stimulator designed for sport and fitness, but with special attention also for beauty treatments thanks to the new sequential stimulation currents, excellent for their draining effects.
Study: NCT05597462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride capsules
Description: Minocycline hydrochloride capsules, 40 mg will be administered orally once daily for 16 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be administered orally once daily for 16 weeks.
Study: NCT05128383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab a human monoclonal antibody of the immunoglobulin G4 subclass that inhibits interleukin (IL)-4 and IL-13 signaling by specifically binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes.
Study: NCT03525951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Milieu Teaching
Description: The parent training will incorporate the EMT strategies of responsive interaction, matched turns, language modeling, and expansions. There will be three, hour-long parent training sessions following the teach-model-coach-review format (TMCR). The TMCR framework teaching component will involve 10 minutes of verbal and visual instruction on the language stimulation target of interest. The teaching component will be followed by 15 minutes of clinician modeling of the target strategies with the child while the parent watches. The parent will then have the opportunity to practice using the strategy during naturalistic interaction with their child. The clinician will provide individualized coaching on the use of the target strategy during this 20-minute, parent-child interaction. Finally, the clinician will review the target strategies and set goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Milieu Teaching
Description: The parent training will incorporate the EMT strategies of responsive interaction, matched turns, language modeling, and expansions. There will be three, hour-long parent training sessions following the teach-model-coach-review format (TMCR). The TMCR framework teaching component will involve 10 minutes of verbal and visual instruction on the language stimulation target of interest. The teaching component will be followed by 15 minutes of clinician modeling of the target strategies with the child while the parent watches. The parent will then have the opportunity to practice using the strategy during naturalistic interaction with their child. The clinician will provide individualized coaching on the use of the target strategy during this 20-minute, parent-child interaction. Finally, the clinician will review the target strategies and set goals.

Intervention type: OTHER
Group type: OTHER
Intervention: no intervention comparison group
Description: No intervention for observational (Study 1 and 2) and training (Study 2) data comparison.

Intervention type: OTHER
Group type: OTHER
Intervention: no intervention comparison group
Description: No intervention for observational (Study 1 and 2) and training (Study 2) data comparison.

Intervention type: OTHER
Group type: OTHER
Intervention: no intervention comparison group
Description: No intervention for observational (Study 1 and 2) and training (Study 2) data comparison.
Study: NCT05444959

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB supplementation
Description: Group taking oral HMB free acid supplementation in a blinded liquid form.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Group taking oral supplementation with placebo (in a blinded liquid form).